About TrkA-NAM The TrkA-NAM project, which is in research phase, is focused on the treatment of pain. The target mechanism, NGF / TrkA signaling, is well-validated both preclinically and clinically ...
STOCKHOLM, SE / ACCESS Newswire / May 6, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on ...
"In our TrkA-NAM program, we have identified highly potent and selective TrkA-NAM substances, including ACD137, and demonstrated pain relief in preclinical models in vivo, both in neuropathic and ...
Shares of short squeeze stock Troika Media Group (NASDAQ:TRKA) collapsed 40% on March 7 after the firm released its latest financial report. It was bad. Although the firm posted a robust $187.9 ...
Troika Media Group (NASDAQ:TRKA) has been a popular meme stock so far in 2023. Even after tanking following a short squeeze in early March, TRKA stock remains up by more than 135% year-to-date. What ...
All week, Troika Media (NASDAQ:TRKA) has been catching investors’ attention. Given the volatility in TRKA stock, that’s not too surprising. To recap, Troika shares erupted on Monday, ending the day ...
Purdue Pharma said today it will acquire from VM Pharma full worldwide development and commercial rights to a first-in-class, allosteric selective tropomyosin receptor kinase A (TrkA) inhibitor ...
STOCKHOLM, SE / ACCESS Newswire / August 5, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results